Recombinant influenza virus vaccine tetravalent - Adimmune Corporation

Drug Profile

Recombinant influenza virus vaccine tetravalent - Adimmune Corporation

Alternative Names: Tetravalent influenza vaccine - Adimmune

Latest Information Update: 08 Nov 2016

Price : $50

At a glance

  • Originator Adimmune Corporation
  • Developer Adimmune Corporation; Protein Sciences Corporation
  • Class Anti-infectives; Influenza virus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza virus infections

Most Recent Events

  • 21 Oct 2016 Phase-III clinical trials in Influenza virus infections in Belgium (IM)
  • 21 Oct 2016 Preregistration for Influenza virus infections in Taiwan (IM)
  • 21 Oct 2016 Registered for Influenza virus infections in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top